or about 14% of Medicare Part D’s prescription drug costs, according to CMS. The negotiated prices for the drugs will take effect in 2027. The second round of negotiations builds on the success ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

Dr. Mehmet Oz, the former surgeon and television host, was nominated to head the Centers for Medicare and Medicaid Services.

Opens in a new tab or window Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel ... Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction ...

CMS should monitor the effect on Medicare standalone prescription drug plans of changes in how the drug costs of high-cost ...

CMS is planning to negotiate prices on another 15 drugs this year ... In another provision, the IRA essentially stated that Medicare Part D members would not have to pay more than $2,000 per ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

Once a proponent of Medicare Advantage plans, Oz vowed Friday to go after those plans if they unfairly raise costs for the ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

Former GOP Rep. Larry Bucshon, who retired from Congress in January, is cautioning his Republican colleagues that cutting Medicaid could be politically perilous.

March 14 (Reuters) - All drug manufacturers, including Novo Nordisk (NOVOb.CO), opens new tab and Teva Pharmaceuticals (TEVA.TA), opens new tab, whose medicines are part of the second round of ...